1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. News
  7. Most relevant
    OPS   CA6838231083

OPSENS INC.

(OPS)
  Report
Delayed Toronto Stock Exchange  -  05/13 03:59:55 pm EDT
1.810 CAD   +9.70%
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about OPSENS INC.
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
04/13TRANSCRIPT : Opsens Inc., Q2 2022 Earnings Call, Apr 13, 2022
CI
04/13OPSENS : CEO Certification
PU
04/13OPSENS : CFO Certification
PU
04/13Opsens Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Februa..
CI
04/13OpSens Swings to Loss in Fiscal Q2 as Consolidated Sales Drop
MT
04/13OPSENS BRIEF : Net loss was $2.4 million in Q2 2022 compared with a net income of $41,000 ..
MT
04/13OPSENS BRIEF : Consolidated sales were $8.1 million in Q2 2022, compared with $8.8 million..
MT
04/13Opsens announces second quarter fiscal 2022 financial results
AQ
04/06Opsens to host second quarter fiscal year 2022 financial results conference call on wed..
AQ
03/14OpSens to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 15th t..
AQ
02/25OpSens Reports on Voting Results from its Annual Shareholders Meeting
AQ
02/09Opsens appoints brad davis as new chief commercial officer
AQ
02/09OpSens Inc Appoints Brad Davis as Chief Commercial Officer
CI
02/01Toronto Stocks Rise; Couche-Tard Rises After Increased Buyback
DJ
02/01OpSens Details Abiomed 4-Year Supply Agreement Extension to 2028
MT
02/01Opsens announces abiomed 4-year supply agreement extension to 2028
AQ
02/01OpSens Inc. Announces Abiomed 4-Year Supply Agreement Extension to 2028
CI
01/28OPSENS : Corrected and Refiled Financial Statements 2021
PU
01/28OPSENS : Form 52-109f1r
PU
01/24Opsens named to 2022 otcqx best 50
AQ
01/13OPSENS : 52-109 F2 CEO Certification
PU
01/13OPSENS : 52-109 F2 CFO Certification
PU
01/13TRANSCRIPT : Opsens Inc., Q1 2022 Earnings Call, Jan 13, 2022
CI
01/13Opsens Inc. Reports Earnings Results for the First Quarter Ended November 30, 2021
CI
01/13OpSens Reports Q1 Loss of $0.02 Per Diluted Share, as Q1 Revenue Misses Forecast
MT
01/13OPSENS BRIEF : Q1 Revs $8.096 Million Vs Forecast 8.53 Million and Last Year 8.34 Million
MT
01/13OPSENS BRIEF : Q1 EPS Basic and Diluted ($0.02) Vs Forecast EPS Normalized ($0.01) As Per ..
MT
01/13OpSens Announces FIRST Quarter fiscal 2022 Financial Results
AQ
01/06Opsens to host first quarter fiscal year 2022 financial results conference call on thur..
AQ
2021OPSENS : Annual Information Form
PU
2021OPSENS : Management information circular - English
PU
2021OPSENS : Notice of meeting - French
PU
2021OPSENS : Proxy
PU
2021OPSENS : Management Information Circular
PU
2021OPSENS : Annual Report 2021
PU
2021OpSens Announcing Submission To U.S. FDA For New Guidewire For TAVR Procedure
MT
2021OPSENS BRIEF : Announcing Submission To U.S. FDA For New Guidewire For TAVR Procedure
MT
2021Opsens announces 510(k) submission to u.s. fda for new guidewire for the tavr procedure
AQ
2021Opsens Inc. Announces 510(K) Submission to U.S. FDA for New Guidewire for the Tavr Proc..
CI
2021OPSENS TO PRESENT AT THE LYTHAM PART : Presentation at 11 Am (ET), Monday December 13, 202..
AQ
2021OPSENS : Certification CEO
PU
2021OPSENS : Certification CFO
PU
2021Opsens Upgraded to Strong Buy at Raymond James
MT
2021OpSens Reports Q4 $1.2 Million Net Loss; Successfully Completes 20-Patient in Human Cli..
MT
2021OPSENS BRIEF : Adds Net Loss was $1.2 Million during Q4 2021 Vs Net Income of $0.6 Million..
MT
2021OPSENS BRIEF : Says Total Revenue was $8.1 Million in Q4 2021 Compared With $7.6 million i..
MT
2021OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results
AQ
2021Opsens Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended August ..
CI
2021OPSENS BRIEF : Says Successfully Completed 20-Patient in Human Clinical Study for TAVR Pro..
MT
2021OpSens Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure
AQ
2021Opsens Inc. Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedur..
CI
2021OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Ye..
AQ
2021OpSens will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genu..
AQ
2021OPSENS' SAVVYWIRE™ Featured at the Transcatheter Cardiovascular Therapeutics 2021..
AQ
2021OPSENS : Says "Successfully Treats" First Patients in Human Clinical Study for TAVR Proced..
MT
2021OPSENS : Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
AQ
2021OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
CI
2021OPSENS : to Present at the Lytham Partners Fall 2021 Investor Conference
AQ
2021OPSENS : Shares Rise 4% on Health Canada Approval, Raymond James Says Edwards Lifesciences..
MT
2021OPSENS : Receives Health Canada Approval to Initiate First In-Man Clinical Study For Its S..
MT
2021OPSENS : Receives Approval from Health Canada to Initiate First In-Man Clinical Study for ..
AQ
2021OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for..
CI
2021OPSENS : Appoints Lori Chmura to its Board of Directors
AQ
2021Opsens Inc. Appoints Lori Chmura to Board of Directors
CI
2021TRANSCRIPT : Opsens Inc., Q3 2021 Earnings Call, Jul 13, 2021
CI
2021Opsens Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2021
CI
2021OPSENS : Reports Q3 Loss Per Share of $0.01, Below Forecast
MT
2021OPSENS BRIEF : Q3 Basic and Diluted Loss Per Share $0.01 Vs Forecast $0.00 As Per Capital ..
MT
2021OPSENS : Announces Third Quarter Fiscal 2021 Record Financial Results
AQ
2021NORTH AMERICAN MORNING BRIEFING : Investors Gear -2-
DJ
2021OPSENS : to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesd..
AQ
2021OPSENS : Gets Funding Support to Jointly Develop Optical-Based Fuel Monitoring System For ..
MT
1  2  3Next
Upcoming event on OPSENS INC.